Ontology highlight
ABSTRACT: Background
In 1995, Health Canada started collecting fees from pharmaceutical companies for various drug regulatory activities. This study investigated whether this change in the source of revenue affected the postmarket safety of drugs.Methods
A list of all new active substances approved in the 5 years before (1990-1994) and after (1995-1999) the introduction of cost recovery was compiled. Drug safety warnings and market withdrawals due to safety reasons were identified from the Health Canada Web site and other sources. Information about total funding for Health Canada's drug regulatory program came from a report by KPMG, a global professional service company providing financial audit, tax and advisory services. Time-series analyses and Kaplan-Meier curves were used to det
SUBMITTER: Lexchin J
PROVIDER: S-EPMC6201714 | biostudies-literature | 2018 Oct-Dec
REPOSITORIES: biostudies-literature